Publications from OUS - Clinical Addiction Research

288 publications found

Publications 2024

  1. Abdullah R, Bjørnebekk A, Hauger LE, Hullstein IR, Edvardsen T, Haugaa KH, Almaas VM (2024)
    Severe biventricular cardiomyopathy in both current and former long-term users of anabolic-androgenic steroids
    Eur J Prev Cardiol, 31 (5), 599-608
    DOI 10.1093/eurjpc/zwad362, PubMed 37992194
  2. Bramness JG, Edland-Gryt M (2024)
    [Not Available]
    Tidsskr Nor Laegeforen, 144
    DOI 10.4045/tidsskr.24.0247, PubMed 38738574
  3. Bramness JG, Hjellvik V, Høye A, Tesli M, Haram M, Nystad W, Krokstad S (2024)
    The epidemiology of major depression among adults in Norway: an observational study on the concurrence between population surveys and registry data - a NCDNOR project
    BMC Public Health, 24 (1), 1330
    DOI 10.1186/s12889-024-18754-w, PubMed 38755615
  4. Bukten A, Virtanen S, Hesse M, Chang Z, Kvamme TL, Thylstrup B, Tverborgvik T, Skjærvø I, Stavseth MR (2024)
    The prevalence and comorbidity of mental health and substance use disorders in Scandinavian prisons 2010-2019: a multi-national register study
    BMC Psychiatry, 24 (1), 95
    DOI 10.1186/s12888-024-05540-6, PubMed 38317111
  5. Bukten A, Virtanen S, Hesse M, Thylstrup B, Kvamme TL, Seid AK, Chang Z, Skjærvø I, Tverborgvik T, Stavseth MR (2024)
    The prevalence of substance use disorders among people in Norwegian, Danish and Swedish prisons: A multi-national cohort study, 2010-19
    Addiction (in press)
    DOI 10.1111/add.16477, PubMed 38529890
  6. Finstad J, Røise O, Clausen T, Rosseland LA, Havnes IA (2024)
    A qualitative longitudinal study of traumatic orthopaedic injury survivors' experiences with pain and the long-term recovery trajectory
    BMJ Open, 14 (1), e079161
    DOI 10.1136/bmjopen-2023-079161, PubMed 38191252
  7. Gainullin M, Federico L, Røkke Osen J, Chaban V, Kared H, Alirezaylavasani A, Lund-Johansen F, Wildendahl G, Jacobsen JA, Sarwar Anjum H, Stratford R, Tennøe S, Malone B, Clancy T, Vaage JT, Henriksen K, Wüsthoff L, Munthe LA (2024)
    People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination
    Front Immunol, 14, 1235210
    DOI 10.3389/fimmu.2023.1235210, PubMed 38299149
  8. Gregersen I, Scarth ME, Abdullah R, Thorsby PM, Hauger LE, Haugaa KH, Sagen EL, Michelsen AE, Ueland T, Edvardsen T, Aukrust P, Almaas VM, Bjørnebekk AK, Halvorsen B (2024)
    Elevated interleukin 8 and matrix metalloproteinase 9 levels are associated with myocardial pathology in users of Anabolic-Androgenic Steroids
    Eur J Prev Cardiol (in press)
    DOI 10.1093/eurjpc/zwae126, PubMed 38573232
  9. Havig SM, Berg-Pedersen RM, Krabseth HM, Müller LD, Haugaa K, Zare HK, Gjesdal K, Krajci P, Opdal MS (2024)
    Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients
    Basic Clin Pharmacol Toxicol, 134 (4), 519-530
    DOI 10.1111/bcpt.13982, PubMed 38308508
  10. Henriksen HCB, Havnes IA, Jørstad ML, Abdullah R, Thorsby PM, Hauger LE, Edvardsen T, Haugaa KH, Almaas VM, Bjørnebekk A (2024)
    Treatment-seeking behavior and cardiovascular morbidity among men with anabolic-androgenic steroid use: A cross-sectional study
    Scand J Med Sci Sports, 34 (1), e14554
    DOI 10.1111/sms.14554, PubMed 38268076
  11. Høiland K, Arnevik EA, Egeland J (2024)
    Alcohol use disorder and fitness to drive: Discrepancies between health professionals’ evaluations and objective measures of alcohol use and cognitive functioning
    Nordic Studies on Alcohol and Drugs, 0, 1-13
    DOI 10.1177/1455072523121997, PublikaID 481
  12. Johannessen DA, Overå S, Arnevik EA (2024)
    The role of contextual factors in avenues to recover from gambling disorder: a scoping review
    Front Psychol, 15, 1247152
    DOI 10.3389/fpsyg.2024.1247152, PubMed 38410405
  13. Klonteig S, Scarth M, Bjørnebekk A (2024)
    Sleep pathology and use of anabolic androgen steroids among male weightlifters in Norway
    BMC Psychiatry, 24 (1), 62
    DOI 10.1186/s12888-024-05516-6, PubMed 38254047
  14. Myklebust LH, Eide D, Arnevik EA, Dadras O, De Pirro S, Ellefsen R, Fadnes LT, Hesse M, Kvamme TL, Melis F, Oldervoll A, Thylstrup B, Wusthoff LEC, Clausen T (2024)
    Evaluation of heroin-assisted treatment in Norway: protocol for a mixed methods study
    BMC Health Serv Res, 24 (1), 398
    DOI 10.1186/s12913-024-10767-w, PubMed 38553691
  15. Rodríguez-Cano R, Lotre K, von Soest T, Rognli EB, Bramness JG (2024)
    Loneliness in adolescence and prescription of psychotropic drugs in adulthood: 23-year longitudinal population-based and registry study
    BJPsych Open, 10 (2), e61
    DOI 10.1192/bjo.2024.22, PubMed 38465662
  16. Rognli EB, Høye A, Bramness JG (2024)
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al
    Am J Psychiatry, 181 (2), 168-169
    DOI 10.1176/appi.ajp.20230522, PubMed 38298080
  17. Svendsen VG, Bukten A, Skardhamar T, Stavseth MR (2024)
    Mortality in women with a history of incarceration in Norway: a 20-year national cohort study
    Int J Epidemiol, 53 (2)
    DOI 10.1093/ije/dyae032, PubMed 38481122

Publications 2023

  1. Andersen SN, Hyatt JM, Lobmaier P, Stavseth MR, Bukten A (2023)
    Leaving Their Drugs at the Gate? Exploring Changes in Drug Use From Before to During Incarceration in Norway
    Int J Offender Ther Comp Criminol, 306624X231168596 (in press)
    DOI 10.1177/0306624X231168596, PubMed 37312513
  2. Bramness JG, Edland-Gryt M (2023)
    [Not Available]
    Tidsskr Nor Laegeforen, 143 (1)
    DOI 10.4045/tidsskr.23.0680, PubMed 38258712
  3. Bramness JG, Syse A, Rognli EB (2023)
    [Substance-induced psychosis – a problematic diagnosis]
    Tidsskr Nor Laegeforen, 143 (3)
    DOI 10.4045/tidsskr.22.0762, PubMed 36811432
  4. Bukten A, Skjærvø I, Stavseth MR (2023)
    Exploring mental health comorbidities and opioid agonist treatment coverage among people in prison: A national cohort study 2010-2019
    Drug Alcohol Depend, 250, 110896
    DOI 10.1016/j.drugalcdep.2023.110896, PubMed 37515826
  5. Ellefsen R, Wüsthoff LEC, Arnevik EA (2023)
    Patients' satisfaction with heroin-assisted treatment: a qualitative study
    Harm Reduct J, 20 (1), 73
    DOI 10.1186/s12954-023-00808-8, PubMed 37312181
  6. Ellingsen MM, Clausen T, Johannesen SL, Martinsen EW, Hallgren M (2023)
    Effects of Acute Exercise on Affect, Anxiety, and Self-Esteem in Poly-Substance Dependent Inpatients
    Eur Addict Res, 29 (4), 285-293
    DOI 10.1159/000531042, PubMed 37393901
  7. Henriksen HCB, Havnes IA, Jørstad ML, Bjørnebekk A (2023)
    Health service engagement, side effects and concerns among men with anabolic-androgenic steroid use: a cross-sectional Norwegian study
    Subst Abuse Treat Prev Policy, 18 (1), 19
    DOI 10.1186/s13011-023-00528-z, PubMed 37013635
  8. Jamt REG, Bukten A, Stavseth MR, Bogstrand ST, Tverborgvik T (2023)
    All-cause and cause-specific mortality among individuals imprisoned for driving under the influence of alcohol and drugs in Norway (2000-2016): a retrospective cohort study
    BMJ Open, 13 (12), e078848
    DOI 10.1136/bmjopen-2023-078848, PubMed 38159948
  9. Jørstad ML, Scarth M, Torgersen S, Pope HG, Bjørnebekk A (2023)
    Clustering psychopathology in male anabolic-androgenic steroid users and nonusing weightlifters
    Brain Behav, 13 (7), e3040
    DOI 10.1002/brb3.3040, PubMed 37150843
  10. Malme KB, Ulstein K, Finbråten AK, Wüsthoff LEC, Kielland KB, Hauge J, Dalgard O, Midgard H (2023)
    Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study
    Int J Drug Policy, 116, 104044
    DOI 10.1016/j.drugpo.2023.104044, PubMed 37149914
  11. Næss O, Ekeland TJ, Arnevik EA, Aarstad J, Lid TG (2023)
    Governing by commissioning services - Implementing alcohol screening and brief interventions in hospital settings in Norway
    Eval Program Plann, 98, 102271
    DOI 10.1016/j.evalprogplan.2023.102271, PubMed 36921405
  12. Rognli EB, Dalsrud MK, Wüsthoff LEC, Arnevik EA (2023)
    [Poor uptake of service provision at a drug-related emergency department – a qualitative study]
    Tidsskr Nor Laegeforen, 143 (5)
    DOI 10.4045/tidsskr.22.0471, PubMed 36987889
  13. Rognli EB, Heiberg IH, Jacobsen BK, Høye A, Bramness JG (2023)
    Transition From Substance-Induced Psychosis to Schizophrenia Spectrum Disorder or Bipolar Disorder
    Am J Psychiatry, 180 (6), 437-444
    DOI 10.1176/appi.ajp.22010076, PubMed 37132221
  14. Scarth M, Hauger LE, Thorsby PM, Leknes S, Hullstein IR, Westlye LT, Bjørnebekk A (2023)
    Supraphysiological testosterone levels from anabolic steroid use and reduced sensitivity to negative facial expressions in men
    Psychopharmacology (Berl), 241 (4), 701-715
    DOI 10.1007/s00213-023-06497-2, PubMed 37993638
  15. Scarth M, Westlye LT, Havnes IA, Bjørnebekk A (2023)
    Investigating anabolic-androgenic steroid dependence and muscle dysmorphia with network analysis among male weightlifters
    BMC Psychiatry, 23 (1), 342
    DOI 10.1186/s12888-023-04781-1, PubMed 37193971
  16. Skauen JE, Pallesen S, Bjørnebekk A, Chegeni R, Syvertsen A, Petróczi A, Sagoe D (2023)
    Prevalence and correlates of androgen dependence: a meta-analysis, meta-regression analysis and qualitative synthesis
    Curr Opin Endocrinol Diabetes Obes, 30 (6), 309-323
    DOI 10.1097/MED.0000000000000822, PubMed 37410490
  17. Stavseth MR (2023)
    [Remember to clean the data before use!]
    Tidsskr Nor Laegeforen, 143 (2)
    DOI 10.4045/tidsskr.22.0825, PubMed 36718890
  18. Svendsen VG, Stavseth MR, Skardhamar T, Bukten A (2023)
    Psychiatric morbidity among women in Norwegian prisons, 2010-2019: a register-based study
    BMC Psychiatry, 23 (1), 390
    DOI 10.1186/s12888-023-04886-7, PubMed 37268924
  19. Tverborgvik T, Stavseth MR, Bukten A (2023)
    The association between drug use and mortality in a norwegian prison cohort: a prospective cohort study
    Health Justice, 11 (1), 22
    DOI 10.1186/s40352-023-00223-y, PubMed 37058181

Publications 2022

  1. Bjørnebekk A, Scarth M, Neupane SP, Westlye LT, Hullstein IR, Thorsby PM, Halvorsen B (2022)
    Use of High-Dose Androgens Is Associated with Reduced Brain-Derived Neurotrophic Factor in Male Weightlifters
    Neuroendocrinology, 113 (1), 36-47
    DOI 10.1159/000526418, PubMed 35944495
  2. Bolstad I, Alakokkare AE, Bramness JG, Rognli EB, Levola J, Mustonen A, Miettunen J, Niemelä S (2022)
    The relationships between use of alcohol, tobacco and coffee in adolescence and mood disorders in adulthood
    Acta Psychiatr Scand, 146 (6), 594-603
    DOI 10.1111/acps.13506, PubMed 36177725
  3. Bramness JG (2022)
    [Antidepressants are not addictive]
    Tidsskr Nor Laegeforen, 142 (13)
    DOI 10.4045/tidsskr.22.0562, PubMed 36164795
  4. Bukten A, Lokdam NT, Skjærvø I, Ugelvik T, Skurtveit S, Gabrhelík R, Skardhamar T, Lund IO, Havnes IA, Rognli EB, Chang Z, Fazel S, Friestad C, Hesse M, Lothe J, Ploeg G, Dirkzwager AJE, Clausen T, Tjagvad C, Stavseth MR (2022)
    PriSUD-Nordic-Diagnosing and Treating Substance Use Disorders in the Prison Population: Protocol for a Mixed Methods Study
    JMIR Res Protoc, 11 (3), e35182
    DOI 10.2196/35182, PubMed 35320114
  5. Bukten A, Skjærvø I, Stavseth MR (2022)
    The association of prison security level with mortality after release from prison: a retrospective national cohort study (2000-16)
    Lancet Public Health, 7 (7), e583-e592
    DOI 10.1016/S2468-2667(22)00107-4, PubMed 35779542
  6. Bækkelund H, Ulvenes P, Boon-Langelaan S, Arnevik EA (2022)
    Group treatment for complex dissociative disorders: a randomized clinical trial
    BMC Psychiatry, 22 (1), 338
    DOI 10.1186/s12888-022-03970-8, PubMed 35578194
  7. Edvardsen HME, Aamodt C, Bogstrand ST, Krajci P, Vindenes V, Rognli EB (2022)
    Concentrations of psychoactive substances in blood samples from non-fatal and fatal opioid overdoses
    Br J Clin Pharmacol, 88 (10), 4494-4504
    DOI 10.1111/bcp.15365, PubMed 35470456
  8. Finstad J, Clausen T, Rosseland LA, Røise O, Havnes IA (2022)
    Patient Experiences after Physical Trauma: The Negative Effect of the COVID-19 Pandemic on Recovery
    Int J Environ Res Public Health, 19 (19)
    DOI 10.3390/ijerph191912258, PubMed 36231553
  9. Kildal E, Hassel B, Bjørnebekk A (2022)
    ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
    Sci Rep, 12 (1), 9479
    DOI 10.1038/s41598-022-12977-w, PubMed 35676515
  10. Lokdam NT, Stavseth MR, Bukten A (2022)
    Drug use and re-imprisonment: A prospective study of the Norwegian Offender Mental Health and Addiction (NorMA) cohort
    Drug Alcohol Depend Rep, 5, 100127
    DOI 10.1016/j.dadr.2022.100127, PubMed 36844156
  11. Melsom HS, Heiestad CM, Eftestøl E, Torp MK, Gundersen K, Bjørnebekk AK, Thorsby PM, Stensløkken KO, Hisdal J (2022)
    Reduced arterial elasticity after anabolic-androgenic steroid use in young adult males and mice
    Sci Rep, 12 (1), 9707
    DOI 10.1038/s41598-022-14065-5, PubMed 35690664
  12. Myhre MØ, Walby FA, Bramness JG, Mehlum L (2022)
    Trajectories of Service Contact before Suicide in People with Substance Use Disorders-A National Register Study
    Arch Suicide Res, 28 (1), 200-215
    DOI 10.1080/13811118.2022.2151959, PubMed 36472383
  13. Pape H, Lobmaier P, Bukten A (2022)
    An evaluation of eight short versions of the Drug Use Disorder Identification Test (DUDIT). A prison population study
    Drug Alcohol Depend Rep, 3, 100043
    DOI 10.1016/j.dadr.2022.100043, PubMed 36845984
  14. Rognli EB, Støme LN, Kværner KJ, Wilhelmsen C, Arnevik EA (2022)
    The effect of employment support integrated in substance use treatment: A health economic cost-effectiveness simulation of three different interventions
    Nordisk Alkohol Nark, 40 (2), 199-211
    DOI 10.1177/14550725221122196, PubMed 37063816
  15. Rognli EB, Taipale H, Hjorthøj C, Mittendorfer-Rutz E, Bramness JG, Heiberg IH, Niemelä S (2022)
    Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016
    Psychol Med, 53 (11), 5246-5255
    DOI 10.1017/S003329172200229X, PubMed 35983644
  16. Scarth M, Havnes IA, Jørstad ML, McVeigh J, Van Hout MC, Westlye LT, Torgersen S, Bjørnebekk A (2022)
    Severity of anabolic steroid dependence, executive function, and personality traits in substance use disorder patients in Norway
    Drug Alcohol Depend, 231, 109275
    DOI 10.1016/j.drugalcdep.2022.109275, PubMed 35030506
  17. Scarth M, Jørstad ML, Reierstad A, Klonteig S, Torgersen S, Hullstein IR, Bjørnebekk A (2022)
    Psychopathology among anabolic-androgenic steroid using and non-using female athletes in Norway
    J Psychiatr Res, 155, 295-301
    DOI 10.1016/j.jpsychires.2022.09.023, PubMed 36170757
  18. Zahl KE, Pedersen G, Eikenaes IU, Stänicke LI, Wilberg T, Baltzersen ÅL, Pettersen MS, Hummelen B, Arnevik E, Johansen MS, Hartveit Kvarstein E (2022)
    Avoidant and borderline personality disorder patients during the first Covid-19 wave in Norway - a survey-based comparison of therapy changes and patients' accommodations
    Nord J Psychiatry, 77 (4), 336-344
    DOI 10.1080/08039488.2022.2110614, PubMed 35984379

Publications 2021

  1. Bech AB, Clausen T, Waal H, Delaveris GJM, Skeie I (2021)
    Organ pathologies detected post-mortem in patients receiving opioid agonist treatment for opioid use disorder: a nation-wide 2-year cross-sectional study
    Addiction, 117 (4), 977-985
    DOI 10.1111/add.15705, PubMed 34648218
  2. Bjørnebekk A, Kaufmann T, Hauger LE, Klonteig S, Hullstein IR, Westlye LT (2021)
    Long-term Anabolic-Androgenic Steroid Use Is Associated With Deviant Brain Aging
    Biol Psychiatry Cogn Neurosci Neuroimaging, 6 (5), 579-589
    DOI 10.1016/j.bpsc.2021.01.001, PubMed 33811018
  3. Bukten A, Stavseth MR (2021)
    Suicide in prison and after release: a 17-year national cohort study
    Eur J Epidemiol, 36 (10), 1075-1083
    DOI 10.1007/s10654-021-00782-0, PubMed 34427828
  4. Bækkelund H, Karlsrud I, Hoffart A, Arnevik EA (2021)
    Stabilizing group treatment for childhood-abuse related PTSD: a randomized controlled trial
    Eur J Psychotraumatol, 12 (1), 1859079
    DOI 10.1080/20008198.2020.1859079, PubMed 33537118
  5. Ellingsen MM, Clausen T, Johannesen SL, Martinsen EW, Hallgren M (2021)
    Effects of acute exercise on drug craving in adults with poly-substance use disorder. A randomized controlled trial
    Ment. Health Phys. Act., 21, 100423
    DOI 10.1016/j.mhpa.2021.100423
  6. Finstad J, Røise O, Rosseland LA, Clausen T, Havnes IA (2021)
    Discharge from the trauma centre: exposure to opioids, unmet information needs and lack of follow up-a qualitative study among physical trauma survivors
    Scand J Trauma Resusc Emerg Med, 29 (1), 121
    DOI 10.1186/s13049-021-00938-7, PubMed 34419130
  7. Hauger LE, Havnes IA, Jørstad ML, Bjørnebekk A (2021)
    Anabolic androgenic steroids, antisocial personality traits, aggression and violence
    Drug Alcohol Depend, 221, 108604
    DOI 10.1016/j.drugalcdep.2021.108604, PubMed 33621808
  8. Havnes IA, Muller AE (2021)
    Nonprescribed androgen use among women and trans men
    Curr Opin Endocrinol Diabetes Obes, 28 (6), 595-603
    DOI 10.1097/MED.0000000000000680, PubMed 34709214
  9. Kvarstein EH, Zahl KE, Stänicke LI, Pettersen MS, Baltzersen ÅL, Johansen MS, Eikenaes IU, Arnevik EA, Hummelen B, Wilberg T, Pedersen G (2021)
    Vulnerability of personality disorder during the Covid-19 crises - a multicenter survey of treatment experiences among patients referred to treatment
    Nord J Psychiatry, 76 (1), 52-63
    DOI 10.1080/08039488.2021.1934110, PubMed 34126854
  10. Midgard H, Ulstein K, Backe Ø, Foshaug T, Sørli H, Vennesland K, Nilssen D, Dahl EH, Finbråten AK, Wüsthoff L, Dalgard O (2021)
    Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway
    Int J Drug Policy, 96, 103165
    DOI 10.1016/j.drugpo.2021.103165, PubMed 33642182
  11. Rognli EB, Bramness JG, von Soest T (2021)
    Smoking in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, antidepressants and anxiolytics
    Psychol Med, 52 (14), 3241-3250
    DOI 10.1017/S0033291720005401, PubMed 33583454
  12. Rognli EB, Aas EM, Drake RE, Marsden J, Anders P, Bond GR, Lystad JU, Reme SE, Arnevik EA (2021)
    The effect evaluation of Individual Placement and Support (IPS) for patients with substance use disorders: study protocol for a randomized controlled trial of IPS versus enhanced self-help
    Trials, 22 (1), 705
    DOI 10.1186/s13063-021-05673-z, PubMed 34654464
  13. Scarth M, Bjørnebekk A (2021)
    Androgen abuse and the brain
    Curr Opin Endocrinol Diabetes Obes, 28 (6), 604-614
    DOI 10.1097/MED.0000000000000675, PubMed 34709215
  14. Stavseth MR (2021)
    STATISTICAL DATA ANALYSIS OF 1-2-3
    Tidsskr. Nor. Laegeforen., 141 (3), 288
  15. Walderhaug E (2021)
    From punishment to help?
    Tidsskr Nor Laegeforen, 141 (9)
    DOI 10.4045/tidsskr.21.0386, PubMed 34107660

Publications 2020

  1. Bech AB, Clausen T, Waal H, Vindenes V, Edvardsen HE, Frost J, Skeie I (2020)
    Post-mortem toxicological analyses of blood samples from 107 patients receiving opioid agonist treatment: substances detected and pooled opioid and benzodiazepine concentrations
    Addiction, 116 (4), 845-855
    DOI 10.1111/add.15211, PubMed 32738014
  2. Bramness JG, Bretteville-Jensen AL (2020)
    [Cannabis – riskier than we thought?]
    Tidsskr Nor Laegeforen, 140 (18)
    DOI 10.4045/tidsskr.20.0801, PubMed 33322880
  3. Bramness JG, Malt UF (2020)
    [Gradual dose reduction of antipsychotic drugs]
    Tidsskr Nor Laegeforen, 140 (10)
    DOI 10.4045/tidsskr.20.0322, PubMed 32602326
  4. Brorson HH, Arnevik EA, Rand-Hendriksen K, Duckert F (2020)
    Corrigendum to "Drop-out from addiction treatment: A systematic review of risk factors"
    Clin Psychol Rev, 76, 101796
    DOI 10.1016/j.cpr.2019.101796, PubMed 32067823
  5. Bukten A, Lund IO, Kinner SA, Rognli EB, Havnes IA, Muller AE, Stavseth MR (2020)
    Factors associated with drug use in prison - results from the Norwegian offender mental health and addiction (NorMA) study
    Health Justice, 8 (1), 10
    DOI 10.1186/s40352-020-00112-8, PubMed 32399643
  6. Ellingsen MM, Johannesen SL, Martinsen EW, Dahl SR, Hallgren M (2020)
    Effects of Acute Exercise on Drug Craving, Self-Esteem, Mood, and Affect in Adults with Polysubstance Use Disorder: Protocol for a Multicenter Randomized Controlled Trial
    JMIR Res Protoc, 9 (10), e18553
    DOI 10.2196/18553, PubMed 33048056
  7. Gatti F, Walderhaug E, Kern-Godal A, Lysell J, Arnevik EA (2020)
    Complementary horse-assisted therapy for substance use disorders: a randomized controlled trial
    Addict Sci Clin Pract, 15 (1), 7
    DOI 10.1186/s13722-020-0183-z, PubMed 32019584
  8. Hauger LE, Westlye LT, Bjørnebekk A (2020)
    Anabolic androgenic steroid dependence is associated with executive dysfunction
    Drug Alcohol Depend, 208, 107874
    DOI 10.1016/j.drugalcdep.2020.107874, PubMed 31972519
  9. Havnes IA (2020)
    DOPING Addiction, vanity and performance
    Tidsskr. Nor. Laegeforen., 140 (5), 496
  10. Havnes IA, Bukten A, Rognli EB, Muller AE (2020)
    Use of anabolic-androgenic steroids and other substances prior to and during imprisonment - Results from the Norwegian Offender Mental Health and Addiction (NorMA) study
    Drug Alcohol Depend, 217, 108255
    DOI 10.1016/j.drugalcdep.2020.108255, PubMed 32949884
  11. Havnes IA, Jørstad ML, Innerdal I, Bjørnebekk A (2020)
    Anabolic-androgenic steroid use among women - A qualitative study on experiences of masculinizing, gonadal and sexual effects
    Int J Drug Policy, 95, 102876
    DOI 10.1016/j.drugpo.2020.102876, PubMed 32736958
  12. Havnes IA, Jørstad ML, McVeigh J, Van Hout MC, Bjørnebekk A (2020)
    The Anabolic Androgenic Steroid Treatment Gap: A National Study of Substance Use Disorder Treatment
    Subst Abuse, 14, 1178221820904150
    DOI 10.1177/1178221820904150, PubMed 32127749
  13. Medved D, Clausen T, Bukten A, Bjørnestad R, Muller AE (2020)
    Large and non-specific somatic disease burdens among ageing, long-term opioid maintenance treatment patients
    Subst Abuse Treat Prev Policy, 15 (1), 87
    DOI 10.1186/s13011-020-00311-4, PubMed 33198799
  14. Mutsaerts HJMM, Petr J, Groot P, Vandemaele P, Ingala S, Robertson AD, Václavů L, Groote I, Kuijf H, Zelaya F, O'Daly O, Hilal S, Wink AM, Kant I, Caan MWA, Morgan C, de Bresser J, Lysvik E, Schrantee A, Bjørnebekk A, Clement P, Shirzadi Z, Kuijer JPA, Wottschel V, Anazodo UC et al. (2020)
    ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies
    Neuroimage, 219, 117031
    DOI 10.1016/j.neuroimage.2020.117031, PubMed 32526385
  15. Pape H, Rossow I, Bukten A (2020)
    Alcohol Problems among Prisoners: Subgroup Variations, Concurrent Drug Problems, and Treatment Needs
    Eur Addict Res, 27 (3), 179-188
    DOI 10.1159/000511253, PubMed 33321498
  16. Paap MCS, Hummelen B, Braeken J, Arnevik EA, Walderhaug E, Wilberg T, Berghuis H, Hutsebaut J, Pedersen G (2020)
    A multi-center psychometric evaluation of the Severity Indices of Personality Problems 118 (SIPP-118): Do we really need all those facets?
    Qual Life Res, 30 (2), 567-575
    DOI 10.1007/s11136-020-02654-8, PubMed 33029679
  17. Rand K, Arnevik EA, Walderhaug E (2020)
    Quality of life among patients seeking treatment for substance use disorder, as measured with the EQ-5D-3L
    J Patient Rep Outcomes, 4 (1), 92
    DOI 10.1186/s41687-020-00247-0, PubMed 33165764
  18. Solli KK, Opheim A, Latif ZE, Krajci P, Benth JŠ, Kunoe N, Tanum L (2020)
    Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone
    Addiction, 116 (8), 2084-2093
    DOI 10.1111/add.15378, PubMed 33338285
  19. Stavseth MR (2020)
    Sensitivity analysis - how robust is the result?
    Tidsskr. Nor. Laegeforen., 140 (8), 807
  20. Tonga JB, Eilertsen DE, Solem IKL, Arnevik EA, Korsnes MS, Ulstein ID (2020)
    Effect of Self-Efficacy on Quality of Life in People With Mild Cognitive Impairment and Mild Dementia: The Mediating Roles of Depression and Anxiety
    Am J Alzheimers Dis Other Demen, 35, 1533317519885264
    DOI 10.1177/1533317519885264, PubMed 31916847
  21. Tonga JB, Šaltytė Benth J, Arnevik EA, Werheid K, Korsnes MS, Ulstein ID (2020)
    Managing depressive symptoms in people with mild cognitive impairment and mild dementia with a multicomponent psychotherapy intervention: a randomized controlled trial
    Int Psychogeriatr, 33 (3), 217-231
    DOI 10.1017/S1041610220000216, PubMed 32131911
  22. Vaskinn A, Hauger LE, Bjørnebekk A (2020)
    Theory of mind in users of anabolic androgenic steroids
    Psychopharmacology (Berl), 237 (10), 3191-3199
    DOI 10.1007/s00213-020-05603-y, PubMed 32623552
  23. Welle-Strand GK, Skurtveit S, Abel KF, Chalabianloo F, Sarfi M (2020)
    Living a normal life? Follow-up study of women who had been in opioid maintenance treatment during pregnancy
    J Subst Abuse Treat, 113, 108004
    DOI 10.1016/j.jsat.2020.108004, PubMed 32359675
  24. Waal H, Vold JH, Skurtveit SO (2020)
    Quetiapine abuse - myth or reality?
    Tidsskr. Nor. Laegeforen., 140 (12), 1228-1230

Publications 2019

  1. Arnevik EA, Pedersen G, Walderhaug E, Lien I, Wilberg T, Hummelen B (2019)
    Measuring Personality Problems in Patients With Substance Use Disorders: A Cross-Sample Validation
    J Dual Diagn, 15 (4), 324-332
    DOI 10.1080/15504263.2019.1668583, PubMed 31571533
  2. Bech AB, Clausen T, Waal H, Šaltytė Benth J, Skeie I (2019)
    Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
    BMC Health Serv Res, 19 (1), 440
    DOI 10.1186/s12913-019-4282-z, PubMed 31266495
  3. Bramness JG (2019)
    [No easy access to health data]
    Tidsskr Nor Laegeforen, 139 (8)
    DOI 10.4045/tidsskr.19.0234, PubMed 31062559
  4. Bramness JG, Vindenes V (2019)
    [Medical cannabis]
    Tidsskr Nor Laegeforen, 139 (15)
    DOI 10.4045/tidsskr.19.0595, PubMed 31642634
  5. Brorson HH, Arnevik EA, Rand K (2019)
    Predicting Dropout from Inpatient Substance Use Disorder Treatment: A Prospective Validation Study of the OQ-Analyst
    Subst Abuse, 13, 1178221819866181
    DOI 10.1177/1178221819866181, PubMed 31452601
  6. Hauger LE, Sagoe D, Vaskinn A, Arnevik EA, Leknes S, Jørstad ML, Bjørnebekk A (2019)
    Anabolic androgenic steroid dependence is associated with impaired emotion recognition
    Psychopharmacology (Berl), 236 (9), 2667-2676
    DOI 10.1007/s00213-019-05239-7, PubMed 30941469
  7. Hauger LE, Westlye LT, Fjell AM, Walhovd KB, Bjørnebekk A (2019)
    Structural brain characteristics of anabolic-androgenic steroid dependence in men
    Addiction, 114 (8), 1405-1415
    DOI 10.1111/add.14629, PubMed 30955206
  8. Havnes IA, Jørstad ML, Wisløff C (2019)
    Anabolic-androgenic steroid users receiving health-related information; health problems, motivations to quit and treatment desires
    Subst Abuse Treat Prev Policy, 14 (1), 20
    DOI 10.1186/s13011-019-0206-5, PubMed 31096999
  9. Helverschou SB, Brunvold AR, Arnevik EA (2019)
    Treating Patients With Co-occurring Autism Spectrum Disorder and Substance Use Disorder: A Clinical Explorative Study
    Subst Abuse, 13, 1178221819843291
    DOI 10.1177/1178221819843291, PubMed 31024216
  10. Latif ZE, Šaltyte Benth J, Solli KK, Opheim A, Kunoe N, Krajci P, Sharma-Haase K, Tanum L (2019)
    Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study
    JAMA Psychiatry, 76 (2), 127-134
    DOI 10.1001/jamapsychiatry.2018.3537, PubMed 30566177
  11. Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci P, Sharma-Haase K, Tanum L (2019)
    No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study
    Am J Addict, 28 (2), 77-85
    DOI 10.1111/ajad.12859, PubMed 30701613
  12. Morland J, Waal H (2019)
    "The entire common catalog" in the treatment of drug disorders
    Tidsskr. Nor. Laegeforen., 139 (3), 240-242
  13. Muller AE, Bukten A (2019)
    Measuring the quality of life of incarcerated individuals
    Int J Prison Health, 15 (1), 1-13
    DOI 10.1108/IJPH-02-2018-0005, PubMed 30827162
  14. Pedersen G, Arnevik EA, Hummelen B, Walderhaug E, Wilberg T (2019)
    Psychometric Properties of the Severity Indices of Personality Problems (SIPP) in Two Samples A Norwegian Community Sample and Clinical Samples of Patients With and Without Personality Disorders
    Eur. J. Psychol. Assess., 35 (5), 698-711
    DOI 10.1027/1015-5759/a000436
  15. Pettersen H, Brodahl M, Rundgren J, Davidson L, Havnes IA (2019)
    Partnering with persons in long-term recovery from substance use disorder: experiences from a collaborative research project
    Harm Reduct J, 16 (1), 40
    DOI 10.1186/s12954-019-0310-x, PubMed 31234878
  16. Rognli EB, Bramness JG, von Soest T (2019)
    Cannabis use in early adulthood is prospectively associated with prescriptions of antipsychotics, mood stabilizers, and antidepressants
    Acta Psychiatr Scand, 141 (2), 149-156
    DOI 10.1111/acps.13104, PubMed 31560790
  17. Solli KK, Kunoe N, Latif ZE, Sharma-Haase K, Opheim A, Krajci P, Gaulen Z, Šaltytė Benth J, Tanum L (2019)
    Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial
    Eur Addict Res, 25 (6), 303-309
    DOI 10.1159/000501931, PubMed 31340204
  18. Sømhovd M, Hagen E, Bergly T, Arnevik EA (2019)
    The Montreal Cognitive Assessment as a predictor of dropout from residential substance use disorder treatment
    Heliyon, 5 (3), e01282
    DOI 10.1016/j.heliyon.2019.e01282, PubMed 31025003
  19. Walderhaug E, Seim-Wikse KJ, Enger A, Milin O (2019)
    Polydrug Use - prevalence and registration
    Tidsskr. Nor. Laegeforen., 139 (13), 1279-1281
  20. Walderhaug E, Seim-Wikse KJ, Enger A, Milin O (2019)
    Polydrug use - prevalence and registration
    Tidsskr Nor Laegeforen, 139 (13)
    DOI 10.4045/tidsskr.19.0251, PubMed 31556532

Publications 2018

  1. Andersson HW, Steinsbekk A, Walderhaug E, Otterholt E, Nordfjærn T (2018)
    Predictors of Dropout From Inpatient Substance Use Treatment: A Prospective Cohort Study
    Subst Abuse, 12, 1178221818760551
    DOI 10.1177/1178221818760551, PubMed 29531472
  2. Bækkelund H, Frewen P, Lanius R, Ottesen Berg A, Arnevik EA (2018)
    Trauma-related altered states of consciousness in post-traumatic stress disorder patients with or without comorbid dissociative disorders
    Eur J Psychotraumatol, 9 (1), 1544025
    DOI 10.1080/20008198.2018.1544025, PubMed 30455853
  3. Ellingsen MM, Johannesen SL, Martinsen EW, Hallgren M (2018)
    Effects of acute exercise on drug craving, self-esteem, mood and affect in adults with poly-substance dependence: Feasibility and preliminary findings
    Drug Alcohol Rev, 37 (6), 789-793
    DOI 10.1111/dar.12818, PubMed 29869351
  4. Fosen JT, Høiseth G, Sempio C, Giarratana N, Enger A, Mørland J, Morini L (2018)
    Hair EtG: Alterations in segment levels accompanying hair growth
    Drug Test Anal, 11 (1), 112-118
    DOI 10.1002/dta.2474, PubMed 30084156
  5. Gjerden P, Bramness JG, Slørdal L (2018)
    [Not Available]
    Tidsskr Nor Laegeforen, 138 (13)
    DOI 10.4045/tidsskr.18.0535, PubMed 30180497
  6. Hagen E, Sømhovd M, Hesse M, Arnevik EA, Erga AH (2018)
    Measuring cognitive impairment in young adults with polysubstance use disorder with MoCA or BRIEF-A - The significance of psychiatric symptoms
    J Subst Abuse Treat, 97, 21-27
    DOI 10.1016/j.jsat.2018.11.010, PubMed 30577896
  7. Heldal AT, Skurtveit S, Lobmaier PPK, Vederhus JK, Bramness JG (2018)
    [Use of drugs for alcohol use disorder in Norway 2004–16]
    Tidsskr Nor Laegeforen, 138 (18)
    DOI 10.4045/tidsskr.18.0383, PubMed 30421743
  8. Henriksen K, Jacobsen JA, Henriksen EM, Gomes L, Waal H, Krajci P (2018)
    The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting
    Eur Addict Res, 24 (6), 286-292
    DOI 10.1159/000495188, PubMed 30466108
  9. Haabrekke K, Siqveland T, Nygaaard E, Bjornebekk A, Slinning K, Wentzel-Larsen T, Walhovd KB, Smith L, Moe V (2018)
    COGNITIVE AND SOCIOEMOTIONAL FUNCTIONING AT 4½ YEARS IN CHILDREN BORN TO MOTHERS WHO HAVE RECEIVED TREATMENT FOR SUBSTANCE-ABUSE PROBLEMS WHILE PREGNANT
    Infant Ment Health J, 39 (5), 581-594
    DOI 10.1002/imhj.21733, PubMed 30084491
  10. Jørstad ML, Skogheim TS, Bergsund HB (2018)
    [Not Available]
    Nordisk Alkohol Nark, 35 (1), 69-76
    DOI 10.1177/1455072517748871, PubMed 32934514
  11. Madah-Amiri D, Skulberg AK, Braarud AC, Dale O, Heyerdahl F, Lobmaier P, Clausen T (2018)
    Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility
    Subst Abus, 40 (3), 383-388
    DOI 10.1080/08897077.2018.1485130, PubMed 29949448
  12. Muller AE, Havnes IA, Rognli EB, Bukten A (2018)
    Inmates with Harmful Substance Use Increase Both Exercise and Nicotine Use Under Incarceration
    Int J Environ Res Public Health, 15 (12)
    DOI 10.3390/ijerph15122663, PubMed 30486386
  13. Ringen PA, Faerden A, Antonsen B, Falk RS, Mamen A, Rognli EB, Solberg DK, Andreassen OA, Martinsen EW (2018)
    Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments
    Nord J Psychiatry, 72 (4), 296-302
    DOI 10.1080/08039488.2018.1449012, PubMed 29523041
  14. Ringen PA, Falk RS, Antonsen B, Faerden A, Mamen A, Rognli EB, Solberg DK, Martinsen EW, Andreassen OA (2018)
    Using motivational techniques to reduce cardiometabolic risk factors in long term psychiatric inpatients: a naturalistic interventional study
    BMC Psychiatry, 18 (1), 255
    DOI 10.1186/s12888-018-1832-6, PubMed 30111298
  15. Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JŠ, Tanum L, Kunoe N (2018)
    Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial
    Addiction, 113 (10), 1840-1849
    DOI 10.1111/add.14278, PubMed 29806872

Publications 2017

  1. Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T (2017)
    High risk of overdose death following release from prison: variations in mortality during a 15-year observation period
    Addiction, 112 (8), 1432-1439
    DOI 10.1111/add.13803, PubMed 28319291
  2. Fosen JT, Morini L, Sempio C, Giarratana N, Enger A, Mørland J, Høiseth G (2017)
    Ethyl Glucuronide Elimination Kinetics in Fingernails and Comparison to Levels in Hair
    Alcohol Alcohol, 52 (5), 580-586
    DOI 10.1093/alcalc/agx035, PubMed 28591773
  3. Hagen E, Erga AH, Hagen KP, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2017)
    One-year sobriety improves satisfaction with life, executive functions and psychological distress among patients with polysubstance use disorder
    J Subst Abuse Treat, 76, 81-87
    DOI 10.1016/j.jsat.2017.01.016, PubMed 28159440
  4. Hagen E, Erga AH, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2017)
    One-year abstinence improves ADHD symptoms among patients with polysubstance use disorder
    Addict Behav Rep, 6, 96-101
    DOI 10.1016/j.abrep.2017.08.005, PubMed 29450242
  5. Kjoesnes R, Waal H, Hauff E, Gossop M (2017)
    Severe trauma among substance users in opioid maintenance treatment: users' assessment of worst trauma and clinical assessment of PTSD
    Heroin Addict. Relat. Clin. Probl., 19 (1), 5-11
  6. Madah-Amiri D, Clausen T, Lobmaier P (2017)
    Rapid widespread distribution of intranasal naloxone for overdose prevention
    Drug Alcohol Depend, 173, 17-23
    DOI 10.1016/j.drugalcdep.2016.12.013, PubMed 28182982
  7. Nyhagen HT, Waal H (2017)
    [Not Available]
    Nordisk Alkohol Nark, 34 (1), 72-79
    DOI 10.1177/1455072516682637, PubMed 32934468
  8. Tanum L, Solli KK, Latif ZE, Benth JŠ, Opheim A, Sharma-Haase K, Krajci P, Kunøe N (2017)
    Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial
    JAMA Psychiatry, 74 (12), 1197-1205
    DOI 10.1001/jamapsychiatry.2017.3206, PubMed 29049469
  9. Wright N, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B (2017)
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model
    Eur J Gastroenterol Hepatol, 29 (11), 1206-1214
    DOI 10.1097/MEG.0000000000000962, PubMed 28914697

Publications 2016

  1. Arnevik EA, Helverschou SB (2016)
    Autism Spectrum Disorder and Co-occurring Substance Use Disorder - A Systematic Review
    Subst Abuse, 10, 69-75
    DOI 10.4137/SART.S39921, PubMed 27559296
  2. Bramness JG, Rognli EB (2016)
    Psychosis induced by amphetamines
    Curr Opin Psychiatry, 29 (4), 236-41
    DOI 10.1097/YCO.0000000000000254, PubMed 27175554
  3. Hagen E, Erga AH, Hagen KP, Nesvåg SM, McKay JR, Lundervold AJ, Walderhaug E (2016)
    Assessment of Executive Function in Patients With Substance Use Disorder: A Comparison of Inventory- and Performance-Based Assessment
    J Subst Abuse Treat, 66, 1-8
    DOI 10.1016/j.jsat.2016.02.010, PubMed 27211990
  4. Henriksen K, Waal H, Krajci P (2016)
    Will non-compliant 'hard-to-treat' opioid-dependent patients profit from low threshold methadone treatment? A prospective 15-month evaluation of patients on Low Dosage Methadone treatment at Oslo University Hospital
    Heroin Addict. Relat. Clin. Probl., 18 (3), 23-27
  5. Kern-Godal A, Brenna IH, Arnevik EA, Ravndal E (2016)
    More Than Just a Break from Treatment: How Substance Use Disorder Patients Experience the Stable Environment in Horse-Assisted Therapy
    Subst Abuse, 10, 99-108
    DOI 10.4137/SART.S40475, PubMed 27746677
  6. Kern-Godal A, Brenna IH, Kogstad N, Arnevik EA, Ravndal E (2016)
    Contribution of the patient-horse relationship to substance use disorder treatment: Patients' experiences
    Int J Qual Stud Health Well-being, 11, 31636
    DOI 10.3402/qhw.v11.31636, PubMed 27291162
  7. Lien IA, Arnevik EA (2016)
    Assessment of personality problems among patients with substance use disorders
    Nord. Stud. Alcohol Drugs, 33 (4), 399-414
    DOI 10.1515/nsad-2016-0033
  8. Madah-Amiri D, Clausen T, Lobmaier P (2016)
    Utilizing a train-the-trainer model for multi-site naloxone distribution programs
    Drug Alcohol Depend, 163, 153-6
    DOI 10.1016/j.drugalcdep.2016.04.007, PubMed 27107847
  9. Madah-Amiri D, Clausen T, Myrmel L, Brattebø G, Lobmaier P (2016)
    Circumstances surrounding non-fatal opioid overdoses attended by ambulance services
    Drug Alcohol Rev, 36 (3), 288-294
    DOI 10.1111/dar.12451, PubMed 28036135
  10. Maremmani I, Rolland B, Somaini L, Roncero C, Reimer J, Wright N, Littlewood R, Krajci P, Alho H, D'Agnone O, Simon N (2016)
    Buprenorphine dosing choices in specific populations: review of expert opinion
    Expert Opin Pharmacother, 17 (13), 1727-31
    DOI 10.1080/14656566.2016.1209486, PubMed 27376622
  11. Nordheim K, Walderhaug E, Alstadius S, Kern-Godal A, Arnevik E, Duckert F (2016)
    Young adults' reasons for dropout from residential substance use disorder treatment
    Qual Soc Work, 17 (1), 24-40
    DOI 10.1177/1473325016654559, PubMed 29276430
  12. Rognli EB, Bramness JG, Skurtveit S, Bukten A (2016)
    Substance use and sociodemographic background as risk factors for lifetime psychotic experiences in a non-clinical sample
    J Subst Abuse Treat, 74, 42-47
    DOI 10.1016/j.jsat.2016.12.007, PubMed 28132699
  13. Westlye LT, Kaufmann T, Alnæs D, Hullstein IR, Bjørnebekk A (2016)
    Brain connectivity aberrations in anabolic-androgenic steroid users
    Neuroimage Clin, 13, 62-69
    DOI 10.1016/j.nicl.2016.11.014, PubMed 27942448

Publications 2015

  1. Alho H, D'Agnone O, Krajci P, McKeganey N, Maremmani I, Reimer J, Roncero C, Somaini L, Wright N, Littlewood R (2015)
    The extent of misuse and diversion of medication for agonist opioid treatment: A review and expert opinions
    Heroin Addict. Relat. Clin. Probl., 17 (2-3), 25-33
  2. Alho H, Jansen J, Krajci P, Littlewood R, Runarsdottir V, Nyberg F (2015)
    Misuse and diversion of agonist opioid treatment medicines: assessment of the scale of the problem and review of the changing environment for care in the Nordic countries
    Heroin Addict. Relat. Clin. Probl., 17 (5), 43-49
  3. Bernard JP, Khiabani HZ, Hilberg T, Karinen R, Slørdal L, Waal H, Mørland J (2015)
    Characteristics of methadone-related fatalities in Norway
    J Forensic Leg Med, 36, 114-20
    DOI 10.1016/j.jflm.2015.09.011, PubMed 26439870
  4. Bramness JG, Henriksen B, Person O, Mann K (2015)
    Reply: To PMID 23921359
    Eur Addict Res, 21 (1), 32
    PubMed 25621344
  5. Bukten A, Lund IO, Rognli EB, Stavseth MR, Lobmaier P, Skurtveit S, Clausen T, Kunøe N (2015)
    The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study
    Subst Abuse, 9 (Suppl 2), 59-66
    DOI 10.4137/SaRt.S23546, PubMed 26648732
  6. Gaasland A, Havnes IA, Venberget M, Andresen JF (2015)
    [Re: All suicides are not due to treatment failure]
    Tidsskr Nor Laegeforen, 135 (18), 1625
    DOI 10.4045/tidsskr.15.0964, PubMed 26442723
  7. Kern-Godal A, Arnevik EA, Walderhaug E, Ravndal E (2015)
    Substance use disorder treatment retention and completion: a prospective study of horse-assisted therapy (HAT) for young adults
    Addict Sci Clin Pract, 10, 21
    DOI 10.1186/s13722-015-0043-4, PubMed 26466788
  8. Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG (2015)
    Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample
    Am J Addict, 24 (7), 586-9
    DOI 10.1111/ajad.12274, PubMed 26332037
  9. Nordal K, Øiestad EL, Enger A, Christophersen AS, Vindenes V (2015)
    Detection Times of Diazepam, Clonazepam, and Alprazolam in Oral Fluid Collected From Patients Admitted to Detoxification, After High and Repeated Drug Intake
    Ther Drug Monit, 37 (4), 451-60
    DOI 10.1097/FTD.0000000000000174, PubMed 25549207
  10. Opdal MS, Arnesen M, Müller LD, Hullstein I, Sayed K, Brørs O, Kringen M, Sagedal S, Gjesdal K, Krajci P (2015)
    Effects of Hemodialysis on Methadone Pharmacokinetics and QTc
    Clin Ther, 37 (7), 1594-9
    DOI 10.1016/j.clinthera.2015.04.009, PubMed 25963997
  11. Reimer J, Wright N, Somaini L, Roncero C, Maremmani I, McKeganey N, Littlewood R, Krajci P, Alho H, D'Agnone O (2015)
    The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus
    Eur Addict Res, 22 (2), 99-106
    DOI 10.1159/000438988, PubMed 26426530
  12. Rognli EB, Berge J, Håkansson A, Bramness JG (2015)
    Long-term risk factors for substance-induced and primary psychosis after release from prison. A longitudinal study of substance users
    Schizophr Res, 168 (1-2), 185-90
    DOI 10.1016/j.schres.2015.08.032, PubMed 26359848
  13. Wright N, D'Agnone O, Krajci P, Littlewood R, Alho H, Reimer J, Roncero C, Somaini L, Maremmani I (2015)
    Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience
    J Public Health (Oxf), 38 (3), e368-e374
    DOI 10.1093/pubmed/fdv150, PubMed 26508767

Publications 2014

  1. Abel KF, Bramness JG, Martinsen EW (2014)
    Stimulant medication for ADHD in opioid maintenance treatment
    J Dual Diagn, 10 (1), 32-8
    DOI 10.1080/15504263.2013.867657, PubMed 25392060
  2. Andås HT, Krabseth HM, Enger A, Marcussen BN, Haneborg AM, Christophersen AS, Vindenes V, Øiestad EL (2014)
    Detection time for THC in oral fluid after frequent cannabis smoking
    Ther Drug Monit, 36 (6), 808-14
    DOI 10.1097/FTD.0000000000000092, PubMed 24819969
  3. Havnes IA, Clausen T, Brux C, Middelthon AL (2014)
    The role of substance use and morality in violent crime - a qualitative study among imprisoned individuals in opioid maintenance treatment
    Harm Reduct J, 11, 24
    DOI 10.1186/1477-7517-11-24, PubMed 25142321
  4. Havnes IA, Clausen T, Middelthon AL (2014)
    Execution of control among 'non-compliant', imprisoned individuals in opioid maintenance treatment
    Int J Drug Policy, 25 (3), 480-5
    DOI 10.1016/j.drugpo.2014.01.018, PubMed 24594221
  5. Kunøe N, Lobmaier P, Ngo H, Hulse G (2014)
    Injectable and implantable sustained release naltrexone in the treatment of opioid addiction
    Br J Clin Pharmacol, 77 (2), 264-71
    DOI 10.1111/bcp.12011, PubMed 23088328
  6. Pettersen H, Ruud T, Ravndal E, Havnes I, Landheim A (2014)
    Engagement in assertive community treatment as experienced by recovering clients with severe mental illness and concurrent substance use
    Int J Ment Health Syst, 8 (1), 40
    DOI 10.1186/1752-4458-8-40, PubMed 25389446
  7. Tveito M, Bramness JG, Engedal K, Lorentzen B, Refsum H, Høiseth G (2014)
    Psychotropic medication in geriatric psychiatric patients: use and unreported use in relation to serum concentrations
    Eur J Clin Pharmacol, 70 (9), 1139-45
    DOI 10.1007/s00228-014-1720-z, PubMed 25031073
  8. Waal H (2014)
    [Advances in the detention cell]
    Tidsskr Nor Laegeforen, 134 (3), 263
    DOI 10.4045/tidsskr.14.0015, PubMed 24518445

Publications 2013

  1. Amble I, Gude T, Stubdal S, Oktedalen T, Skjorten AM, Andersen BJ, Solbakken OA, Brorson HH, Arnevik E, Lambert MJ, Wampold BE (2013)
    Psychometric properties of the outcome questionnaire-45.2: the Norwegian version in an international context
    Psychother Res, 24 (4), 504-13
    DOI 10.1080/10503307.2013.849016, PubMed 24188797
  2. Havnes IA, Clausen T, Middelthon AL (2013)
    'Diversion' of methadone or buprenorphine: 'harm' versus 'helping'
    Harm Reduct J, 10, 24
    DOI 10.1186/1477-7517-10-24, PubMed 24131626
  3. Helseth V, Samet S, Johnsen J, Bramness JG, Waal H (2013)
    Independent or Substance-Induced Mental Disorders? An Investigation of Comorbidity in an Acute Psychiatric Unit
    J. Dual Diagn., 9 (1), 78-86
    DOI 10.1080/15504263.2012.749142
  4. Westin AA, Bramness JG, Chalabianloo F, Slørdal L (2013)
    [A. A. Westin and colleagues reply]
    Tidsskr Nor Laegeforen, 133 (10), 1045-6
    DOI 10.4045/tidsskr.13.0619, PubMed 23712142

Publications 2012

  1. Bernard JP, Havnes I, Slørdal L, Waal H, Mørland J, Khiabani HZ (2012)
    Methadone-related deaths in Norway
    Forensic Sci Int, 224 (1-3), 111-6
    DOI 10.1016/j.forsciint.2012.11.010, PubMed 23246070
  2. Pedersen K, Waal H, Kringlen E (2012)
    Patients with nonaffective psychosis are at increased risk for heroin use disorders
    Eur Addict Res, 18 (3), 124-9
    DOI 10.1159/000334613, PubMed 22354141
  3. Skeie I, Brekke M, Clausen T, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H (2012)
    Increased somatic morbidity in the first year after leaving opioid maintenance treatment: results from a Norwegian cohort study
    Eur Addict Res, 19 (4), 194-201
    DOI 10.1159/000345229, PubMed 23257574
  4. Waal H, Brekke M, Clausen T, Lindbæk M, Rosta J, Skeie I, Aasland OG (2012)
    General practitioners' views on drug-assisted rehabilitation
    Tidsskr Nor Laegeforen, 132 (16), 1861-6
    DOI 10.4045/tidsskr.12.0124, PubMed 22986970

Publications 2011

  1. Bukten A, Skurtveit S, Gossop M, Waal H, Stangeland P, Havnes I, Clausen T (2011)
    Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study
    Addiction, 107 (2), 393-9
    DOI 10.1111/j.1360-0443.2011.03637.x, PubMed 21883606
  2. Bukten A, Skurtveit S, Stangeland P, Gossop M, Willersrud AB, Waal H, Havnes I, Clausen T (2011)
    Criminal convictions among dependent heroin users during a 3-year period prior to opioid maintenance treatment: a longitudinal national cohort study
    J Subst Abuse Treat, 41 (4), 407-14
    DOI 10.1016/j.jsat.2011.06.006, PubMed 21839605
  3. Helland A, Bramness JG (2011)
    [Baclofen for alcohol addiction]
    Tidsskr Nor Laegeforen, 131 (21), 2132-3
    DOI 10.4045/tidsskr.11.0584, PubMed 22048211
  4. Lobmaier PP, Kunøe N, Gossop M, Waal H (2011)
    Naltrexone depot formulations for opioid and alcohol dependence: a systematic review
    CNS Neurosci Ther, 17 (6), 629-36
    DOI 10.1111/j.1755-5949.2010.00194.x, PubMed 21554565
  5. Mordal J, Holm B, Gossop M, Romøren M, Mørland J, Bramness J (2011)
    Psychoactive substance use among patients admitted to an acute psychiatric ward: laboratory findings and associations with clinical characteristics
    Nord J Psychiatry, 65 (3), 208-15
    DOI 10.3109/08039488.2010.527014, PubMed 21047195
  6. Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M, Waal H (2011)
    Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study
    BMJ Open, 1 (1), e000130
    DOI 10.1136/bmjopen-2011-000130, PubMed 22021771
  7. Vindenes V, Yttredal B, Oiestad EL, Waal H, Bernard JP, Mørland JG, Christophersen AS (2011)
    Oral fluid is a viable alternative for monitoring drug abuse: detection of drugs in oral fluid by liquid chromatography-tandem mass spectrometry and comparison to the results from urine samples from patients treated with Methadone or Buprenorphine
    J Anal Toxicol, 35 (1), 32-9
    DOI 10.1093/anatox/35.1.32, PubMed 21219701

Publications 2010

  1. Bramness JG (2010)
    [Abuse of pregabalin]
    Tidsskr Nor Laegeforen, 130 (17), 1703-4
    DOI 10.4045/tidsskr.10.0834, PubMed 20835274
  2. Bramness JG, Clausen T, Duckert F, Ravndal E, Waal H (2010)
    Addiction research centres and the nurturing of creativity The Norwegian Centre for Addiction Research (SERAF)
    Addiction, 106 (8), 1381-5
    DOI 10.1111/j.1360-0443.2010.03086.x, PubMed 20735364
  3. Brekke M, Vetlesen A, Høiby L, Skeie I (2010)
    [Quality of life among patients in drug-assisted rehabilitation programmes]
    Tidsskr Nor Laegeforen, 130 (13), 1340-2
    DOI 10.4045/tidsskr.09.1117, PubMed 20596114
  4. Kornør H, Pedersen W, von Soest T, Rossow I, Bramness JG (2010)
    [Use of benzodiazepines and cannabis in young adults]
    Tidsskr Nor Laegeforen, 130 (9), 928-31
    DOI 10.4045/tidsskr.09.0188, PubMed 20453954
  5. Lobmaier P, Gossop M, Waal H, Bramness J (2010)
    The pharmacological treatment of opioid addiction--a clinical perspective
    Eur J Clin Pharmacol, 66 (6), 537-45
    DOI 10.1007/s00228-010-0793-6, PubMed 20169438
  6. Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H (2010)
    Naltrexone implants compared to methadone: outcomes six months after prison release
    Eur Addict Res, 16 (3), 139-45
    DOI 10.1159/000313336, PubMed 20424458
  7. Ravndal E, Amundsen EJ (2010)
    Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study
    Drug Alcohol Depend, 108 (1-2), 65-9
    DOI 10.1016/j.drugalcdep.2009.11.008, PubMed 20022184
  8. Ravndal E, Vaglum P (2010)
    The Millon Clinical Multiaxial Inventory II: stability over time? A seven-year follow-up study of substance abusers in treatment
    Eur Addict Res, 16 (3), 146-51
    DOI 10.1159/000313337, PubMed 20424459
  9. Waal H (2010)
    NISUD—progress, backlash or sidetrack?
    Addiction, 105 (12), 2050-1; discussion 2056
    DOI 10.1111/j.1360-0443.2010.03116.x, PubMed 21105301
  10. Waal H, Bramness JG (2010)
    [Benzodiazepines to people with substance abuse problems?]
    Tidsskr Nor Laegeforen, 130 (6), 610-2
    DOI 10.4045/tidsskr.09.0687, PubMed 20349006

Publications 2009

  1. Arnevik E, Wilberg T, Monsen JT, Andrea H, Karterud S (2009)
    A cross-national validity study of the Severity Indices of Personality Problems (SIPP-118)
    Personal. Ment. Health, 3 (1), 41-55
    DOI 10.1002/pmh.60
  2. Bramness JG (2009)
    [Adolescents and everyday life pains]
    Tidsskr Nor Laegeforen, 129 (15), 1444
    DOI 10.4045/tidsskr.09.0691, PubMed 19690589
  3. Bramness JG, Walby F (2009)
    Ecological studies and the big puzzle of falling suicide rates
    Acta Psychiatr Scand, 119 (3), 169-70
    DOI 10.1111/j.1600-0447.2008.01318.x, PubMed 19178393
  4. Clausen T, Havnes IA, Waal H (2009)
    [Overdose statistics--a complicated account]
    Tidsskr Nor Laegeforen, 129 (21), 2233-6
    DOI 10.4045/tidsskr.08.0605, PubMed 19898571
  5. Shaygani S, Waal H (2009)
    [Treatment of opioid withdrawal]
    Tidsskr Nor Laegeforen, 129 (2), 114-5
    DOI 10.4045/tidsskr.09.32466, PubMed 19151804
  6. Winther RB, Bramness JG (2009)
    [Prescription shopping of addictive drugs in Norway]
    Tidsskr Nor Laegeforen, 129 (6), 517-20
    DOI 10.4045/tidsskr.09.34414, PubMed 19282887

Publications 2008

  1. Bramness JG (2008)
    [The Somadril Association in Norway]
    Tidsskr Nor Laegeforen, 128 (13), 1545; authorr reply 1545
    PubMed 18587468
  2. Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J (2008)
    Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam
    Sleep Med, 9 (8), 818-22
    DOI 10.1016/j.sleep.2007.11.011, PubMed 18226959
  3. Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG (2008)
    Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors
    Eur J Clin Pharmacol, 65 (3), 295-301
    DOI 10.1007/s00228-008-0565-8, PubMed 18810397
  4. Skeie I, Brekke M, Lindbaek M, Waal H (2008)
    Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study
    BMC Public Health, 8, 43
    DOI 10.1186/1471-2458-8-43, PubMed 18237421
  5. Slørdal L, Bramness JG (2008)
    [Is alimemazine a suitable sleeping agent for children?]
    Tidsskr Nor Laegeforen, 128 (19), 2194-6
    PubMed 18846144

Publications 2007

  1. Bramness JG, Sandvik P, Schøyen H, Walby FA (2007)
    [Weak report about antidepressive agents from the Knowledge Center]
    Tidsskr Nor Laegeforen, 127 (24), 3236-7
    PubMed 18084369
  2. Hausken AM, Skurtveit S, Rosvold EO, Bramness JG, Furu K (2007)
    Psychotropic drug use among persons with mental distress symptoms: a population-based study in Norway
    Scand J Public Health, 35 (4), 356-64
    DOI 10.1080/14034940601159161, PubMed 17786798
  3. Kornør H, Waal H, Sandvik L (2007)
    Time-limited buprenorphine replacement therapy for opioid dependence: 2-year follow-up outcomes in relation to programme completion and current agonist therapy status
    Drug Alcohol Rev, 26 (2), 135-41
    DOI 10.1080/09595230601146603, PubMed 17364848
  4. Kunøe N, Waal H (2007)
    Opioid overdose deaths can occur in patients with naltrexone implants
    Med J Aust, 187 (1), 56; author reply 56-7
    DOI 10.5694/j.1326-5377.2007.tb01124.x, PubMed 17605713
  5. Pedersen K, Sandvik L, Waal H (2007)
    Evaluation of DTES - A simple drug-taking scale
    Addict. Res. Theory, 15 (6), 637-649
    DOI 10.1080/16066350701433209
  6. Skeie I, Brekke M, Lindbaek M, Waal H (2007)
    [General practitioners can take responsibility for medication-based rehabilitation]
    Tidsskr Nor Laegeforen, 127 (3), 296-7
    PubMed 17279108
  7. Waal H, Krook AL, Hansteen V (2007)
    [Methadone treatment and heart arrhythmia]
    Tidsskr Nor Laegeforen, 127 (4), 459; author reply 459-60
    PubMed 17304281
  8. Waal H, Krook AL, Hansteen V (2007)
    [Methadone and arrhythmia--final comment]
    Tidsskr Nor Laegeforen, 127 (7), 913; author reply 913
    PubMed 17435820

Publications 2006

  1. Bramness JG (2006)
    [CYP genotyping in psychopharmacological treatment]
    Tidsskr Nor Laegeforen, 126 (4), 480; author reply 480
    PubMed 16477294
  2. Høiseth G, Bramness JG, Christophersen AS, Mørland J (2006)
    Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003
    Int J Legal Med, 121 (5), 403-9
    DOI 10.1007/s00414-006-0139-1, PubMed 17115170
  3. Høiseth G, Løvåsdal Ø, Titze TK, Bramness JG, Bachs L (2006)
    [Psychiatric and cognitive long-term effects of ecstasy]
    Tidsskr Nor Laegeforen, 126 (5), 596-8
    PubMed 16505868
  4. Khiabani HZ, Bramness JG, Bjørneboe A, Mørland J (2006)
    Relationship between THC concentration in blood and impairment in apprehended drivers
    Traffic Inj Prev, 7 (2), 111-6
    DOI 10.1080/15389580600550172, PubMed 16854704
  5. Kornør H, Waal H, Ali RL (2006)
    Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling
    Drug Alcohol Rev, 25 (2), 123-30
    DOI 10.1080/09595230500537209, PubMed 16627301
  6. Mellingsaeter TC, Bramness JG, Slørdal L (2006)
    [Are z-hypnotics better and safer sleeping pills than benzodiazepines?]
    Tidsskr Nor Laegeforen, 126 (22), 2954-6
    PubMed 17117195

Publications 2005

  1. Gustavsen I, Mørland J, Bramness JG (2005)
    Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers
    Accid Anal Prev, 38 (3), 490-5
    DOI 10.1016/j.aap.2005.11.005, PubMed 16343411
  2. Kornør H, Waal H (2005)
    From opioid maintenance to abstinence: a literature review
    Drug Alcohol Rev, 24 (3), 267-74
    DOI 10.1080/09595230500170241, PubMed 16096130
  3. Kunøe N, Lobmaier P (2005)
    Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005)
    Addiction, 100 (7), 1027-8; author reply 1028-9
    DOI 10.1111/j.1360-0443.2005.01209.x, PubMed 15955020
  4. Olsen V, Gustavsen I, Bramness JG, Hasvold I, Karinen R, Christophersen AS, Mørland J (2005)
    The concentrations, appearance and taste of nine sedating drugs dissolved in four different beverages
    Forensic Sci Int, 151 (2-3), 171-5
    DOI 10.1016/j.forsciint.2005.01.017, PubMed 15939149
  5. Vermund H, Krajci P, Eide TJ, Winther F (2005)
    Histopathological grading of laryngectomy specimens
    APMIS, 113 (7-8), 473-88
    DOI 10.1111/j.1600-0463.2005.apm_24.x, PubMed 16086817

Publications 2004

  1. Kornør H, Waal H (2004)
    [Methadone dose, treatment duration and heroin use in drug-assisted rehabilitation]
    Tidsskr Nor Laegeforen, 124 (3), 332-4
    PubMed 14963504
  2. Krook AL, Waal H, Hansteen V (2004)
    [Routine ECG in methadone-assisted rehabilitation is wrong prioritization]
    Tidsskr Nor Laegeforen, 124 (22), 2940-1
    PubMed 15550974
  3. Olsen L, Christophersen AS, Frogopsahl G, Waal H, Mørland J (2004)
    Plasma concentrations during naltrexone implant treatment of opiate-dependent patients
    Br J Clin Pharmacol, 58 (2), 219-22
    DOI 10.1111/j.1365-2125.2004.02122.x, PubMed 15255807
  4. Vermund H, Krajci P, Eide TJ, Winther F (2004)
    Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate
    Acta Oncol, 43 (1), 98-107
    DOI 10.1080/02841860310020366, PubMed 15068327
  5. Waal H, Kornor H (2004)
    Abstinence-oriented therapies for opiate addicts
    Curr. Opin. Psychiatr., 17 (3), 169-174
    DOI 10.1097/00001504-200405000-00004

Publications 2003

  1. Bachs L, Waal H (2003)
    [Naltrexone in the treatment of addiction]
    Tidsskr Nor Laegeforen, 123 (12), 1665-7
    PubMed 12821984
  2. Waal H (2003)
    [Tragedies in drunk cells]
    Tidsskr Nor Laegeforen, 123 (8), 1047
    PubMed 12760215

Publications 2002

  1. Bramness JG, Bachs LC, Waal H (2002)
    [Buprenorphine as maintenance treatment in rehabilitation of heroin addicts]
    Tidsskr Nor Laegeforen, 122 (25), 2452-4
    PubMed 12448114
  2. Krook AL, Brørs O, Dahlberg J, Grouff K, Magnus P, Røysamb E, Waal H (2002)
    A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway
    Addiction, 97 (5), 533-42
    DOI 10.1046/j.1360-0443.2002.00090.x, PubMed 12033654
  3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
    The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    N Engl J Med, 346 (25), 1937-47
    DOI 10.1056/NEJMoa012914, PubMed 12075054

Publications 2000

  1. Walby FA, Borg P, Eikeseth PH, Neegaard E, Kjerpeseth K, Bruvik S, Waal H (2000)
    [Use of methadone in the treatment of psychotic patients with heroin dependence]
    Tidsskr Nor Laegeforen, 120 (2), 195-8
    PubMed 10851915
  2. Wiatrowska B, Krajci P, Berner A (2000)
    [Pseudo-Meigs' syndrome]
    Tidsskr Nor Laegeforen, 120 (3), 364-6
    PubMed 10827530

Publications 1999

  1. Blix O, Bruvik S, Waal H (1999)
    [The Oslo methadone project]
    Tidsskr Nor Laegeforen, 119 (2), 242-6
    PubMed 10081358
  2. Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzaeg P (1999)
    Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice
    J Exp Med, 190 (7), 915-22
    DOI 10.1084/jem.190.7.915, PubMed 10510081
  3. Nilsen EM, Johansen FE, Kvale D, Krajci P, Brandtzaeg P (1999)
    Different regulatory pathways employed in cytokine-enhanced expression of secretory component and epithelial HLA class I genes
    Eur J Immunol, 29 (1), 168-79
    DOI 10.1002/(SICI)1521-4141(199901)29:01<168::AID-IMMU168>3.0.CO;2-8, PubMed 9933098
  4. Norderhaug IN, Johansen FE, Krajci P, Brandtzaeg P (1999)
    Domain deletions in the human polymeric Ig receptor disclose differences between its dimeric IgA and pentameric IgM interaction
    Eur J Immunol, 29 (10), 3401-9
    DOI 10.1002/(SICI)1521-4141(199910)29:10<3401::AID-IMMU3401>3.0.CO;2-G, PubMed 10540352
  5. Waal H, Morland J (1999)
    Addiction as impeded rationality
    ADDICTION: ENTRIES AND EXITS, 120-147

Publications 1998

  1. Johansen FE, Bosløven BA, Krajci P, Brandtzaeg P (1998)
    A composite DNA element in the promoter of the polymeric immunoglobulin receptor regulates its constitutive expression
    Eur J Immunol, 28 (4), 1161-71
    DOI 10.1002/(SICI)1521-4141(199804)28:04<1161::AID-IMMU1161>3.0.CO;2-S, PubMed 9565355
  2. Waal H (1998)
    [Is methadone a solution?]
    Tidsskr Nor Laegeforen, 118 (20), 3104
    PubMed 9760849
  3. Waal H (1998)
    [Is methadone effective?]
    Tidsskr Nor Laegeforen, 118 (23), 3673
    PubMed 9820017
  4. Waal H (1998)
    [Dogmatism on methadone]
    Tidsskr Nor Laegeforen, 118 (25), 3996
    PubMed 9830350

Publications 1997

  1. Winberg JO, Hammami-Hauasli N, Nilssen O, Anton-Lamprecht I, Naylor SL, Kerbacher K, Zimmermann M, Krajci P, Gedde-Dahl T, Bruckner-Tuderman L (1997)
    Modulation of disease severity of dystrophic epidermolysis bullosa by a splice site mutation in combination with a missense mutation in the COL7A1 gene
    Hum Mol Genet, 6 (7), 1125-35
    DOI 10.1093/hmg/6.7.1125, PubMed 9215684

Publications 1996

  1. Bramness JG (1996)
    [Interruptions of physicians' work at hospitals]
    Tidsskr Nor Laegeforen, 116 (14), 1719
    PubMed 8658445
  2. Bramness JG (1996)
    [Save us from idiocy]
    Tidsskr Nor Laegeforen, 116 (17), 2083
    PubMed 8779151

Publications 1995

  1. Brandtzaeg P, Krajci P (1995)
    The enterocyte and immunoglobulin transport
    Dyn.Nutr.Res., 4, 1-17
  2. Faerden A, Waal H, Rønnow S (1995)
    [Long-term psychiatric patients in a sector of Oslo]
    Tidsskr Nor Laegeforen, 115 (29), 3638-41
    PubMed 8539723
  3. Kamei M, Iwase T, Krajci P, Brandtzaeg P, Moro I (1995)
    Antibody production to secretory component (SC) using recombinant SC fragment
    Adv Exp Med Biol, 371A, 633-5
    DOI 10.1007/978-1-4615-1941-6_133, PubMed 8526006
  4. Kulseth MA, Krajci P, Myklebost O, Rogne S (1995)
    Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA
    DNA Cell Biol, 14 (3), 251-6
    DOI 10.1089/dna.1995.14.251, PubMed 7880445
  5. Moro I, Takahashi T, Iwase T, Asano M, Takenouchi N, Nishimura S, Kudo I, Krajci P, Brandtzaeg P, Moldoveanu Z (1995)
    Expression of SC, IL-6 and TGF-beta 1 in epithelial cell lines
    Adv Exp Med Biol, 371A, 175-82
    DOI 10.1007/978-1-4615-1941-6_36, PubMed 8525901
  6. Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM, Brandtzaeg P (1995)
    Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma
    Gut, 37 (6), 766-76
    DOI 10.1136/gut.37.6.766, PubMed 8537046
  7. Norstein J, Krajci P, Bergan A, Geiran O (1995)
    Intestinal perforation after ingestion of a blister-wrapped tablet
    Lancet, 346 (8985), 1308
    DOI 10.1016/s0140-6736(95)91918-x, PubMed 7475762
  8. Rønnow S, Waal H (1995)
    [Increasing number of involuntary emergency admissions to psychiatric institutions]
    Tidsskr Nor Laegeforen, 115 (19), 2376-80
    PubMed 7667852

Publications 1993

  1. Ersland S, Kringlen E, Waal H, Thaulow JF (1993)
    [Lobotomy at the Gaustad hospital]
    Tidsskr Nor Laegeforen, 113 (17), 2092-5
    PubMed 8337667

Publications 1992

  1. Bramness J (1992)
    [Why change medical education? The reason for changing medical education]
    Tidsskr Nor Laegeforen, 112 (2), 234-5
    PubMed 1566263
  2. Bramness JG (1992)
    [Admission criteria for medical studies]
    Tidsskr Nor Laegeforen, 112 (18), 2390
    PubMed 1412249
  3. Brandtzaeg P, Halstensen TS, Huitfeldt HS, Krajci P, Kvale D, Scott H, Thrane PS (1992)
    Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract
    Ann N Y Acad Sci, 664, 157-79
    DOI 10.1111/j.1749-6632.1992.tb39758.x, PubMed 1456647
  4. BRANDTZAEG P, HALSTENSEN TS, HUITFELDT HS, KRAJCI P, KVALE D, SCOTT H, THRANE PS (1992)
    EPITHELIAL EXPRESSION OF HLA, SECRETORY COMPONENT (POLY-IG RECEPTOR), AND ADHESION MOLECULES IN THE HUMAN ALIMENTARY-TRACT
    Ann.NY Acad.Sci., 664, 157-179
    DOI 10.1111/j.1749-6632.1992.tb39758.x
  5. Kvale D, Krajci P, Brandtzaeg P (1992)
    Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines
    Scand J Immunol, 35 (6), 669-76
    DOI 10.1111/j.1365-3083.1992.tb02973.x, PubMed 1376489
  6. Solberg R, Sistonen P, Träskelin AL, Bérubé D, Simard J, Krajci P, Jahnsen T, de la Chapelle A (1992)
    Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7
    Genomics, 14 (1), 63-9
    DOI 10.1016/s0888-7543(05)80284-8, PubMed 1358799
  7. Waal H (1992)
    [Methadone treatment of narcotic addicts--can it be defended?]
    Tidsskr Nor Laegeforen, 112 (3), 374-5
    PubMed 1553680

Publications 1990

  1. Knutsen T, Waal H (1990)
    [Therapeutic and health care needs of HIV positive drug abusers. A study from an emergency institution]
    Tidsskr Nor Laegeforen, 110 (22), 2861-3
    PubMed 2219061

Publications 1989

  1. Brandtzaeg P, Halstensen TS, Kett K, Krajci P, Kvale D, Rognum TO, Scott H, Sollid LM (1989)
    Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes
    Gastroenterology, 97 (6), 1562-84
    DOI 10.1016/0016-5085(89)90406-x, PubMed 2684725
  2. Helgeland I, Waal H (1989)
    [Can adolescents with behavioral disorders be helped? Problems among young people--behavioral disorders--preventive attempts--follow-up studies--evaluation]
    Tidsskr Nor Laegeforen, 109 (14), 1509-12
    PubMed 2749637
  3. Waal H (1989)
    [Buprenorphine (Temgesic)--a new agent for abuse]
    Tidsskr Nor Laegeforen, 109 (12), 1326-7
    PubMed 2734763
  4. Waal H, Helgeland I (1989)
    [Punishment, fostering, education and treatment. An integrated model for adolescents with behavioral disorders]
    Tidsskr Nor Laegeforen, 109 (14), 1513-6
    PubMed 2749638

Publications 1986

  1. Iversen OH, Krajci P, Thoresen G (1986)
    The fate of epidermal colcemid-arrested mitoses
    Virchows Arch B Cell Pathol Incl Mol Pathol, 51 (2), 115-26
    DOI 10.1007/BF02899022, PubMed 2873676

Publications 1983

  1. Dahl AA, Waal H (1983)
    An outcome study of primal therapy
    Psychother Psychosom, 39 (3), 154-64
    DOI 10.1159/000287736, PubMed 6622628

Publications 1980

  1. Holsten F, Waal H (1980)
    Evaluation of the drug taker. A step to an evaluation of treatment
    Acta Psychiatr Scand Suppl, 284, 29-41
    DOI 10.1111/j.1600-0447.1980.tb10428.x, PubMed 6935930
  2. Holsten F, Waal H (1980)
    The DTES - drug taking evaluation scale. A simple scale for the evaluation of drug taking behaviour
    Acta Psychiatr Scand, 61 (4), 275-305
    DOI 10.1111/j.1600-0447.1980.tb00582.x, PubMed 7446185
  3. Waal H, Holsten F (1980)
    Evaluation of drug taking behaviour. Some theoretical and methodological considerations
    Acta Psychiatr Scand, 61 (2), 127-34
    DOI 10.1111/j.1600-0447.1980.tb00572.x, PubMed 7361585

Publications 1977

  1. Waal H (1977)
    [Ward personnel in the psychiatric hospital keeper, caretaker, nurse or therapist?]
    Sykepleien, 64 (18), 1019-21, 1037
    PubMed 244025
  2. Waal H (1977)
    [Occupational groups and milieu therapy - various comments]
    Sykepleien, 64 (20), 1144-6
    PubMed 245814
  3. Waal H (1977)
    [The new sex therapy]
    Tidsskr Nor Laegeforen, 97 (4), 200-2
    PubMed 841552
  4. Waal H (1977)
    [Role changes for doctors, psychologists and trained social workers during structure changes at the psychiatric hospitals]
    Tidsskr Nor Laegeforen, 97 (16), 846-8
    PubMed 877937
  5. Waal H (1977)
    [Process- or task oriented evaluation?]
    Tidsskr Nor Laegeforen, 97 (19-21), 1001-3
    PubMed 898130
  6. Waal H (1977)
    [Organization and structural changes. Evaluation of open systems]
    Tidsskr Nor Laegeforen, 97 (19-21), 1016-8
    PubMed 898135
  7. Waal H (1977)
    [Evaluation of changes in the structure of a mental hospital]
    Tidsskr Nor Laegeforen, 97 (19-21), 1035-9
    PubMed 898142
  8. Waal H, Baksaas R, Miljeteig M, Sundal N (1977)
    [Team work situation in psychiatric hospital wards are changing]
    Sykepleien, 64 (19), 1086-90
    PubMed 244034

Publications 1973

  1. Waal H (1973)
    [Drug addiction and drug abuse in adolescence]
    Tidsskr Nor Laegeforen, 93 (14), 1047-52
    PubMed 4755947

Publications 1972

  1. Waal H (1972)
    [Chronic "sniffers"]
    Tidsskr Nor Laegeforen, 92 (10), 701-6
    PubMed 5028420

Publications 1971

  1. Kofstad J, Boe G, Waal H (1971)
    [Detection of drug abuse with thin-layer chromatography of urine]
    Tidsskr Nor Laegeforen, 91 (9), 654-6
    PubMed 5576180
  2. Waal H (1971)
    [The present status of adolescent drug addiction in Norway. Theoretical considerations, historical development and treatment offered]
    Tidsskr Nor Laegeforen, 91 (5), 367-74
    PubMed 5546519

 
Page visits: 1828